The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | What do community physicians need to know about managing MF?
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides insight into what community physicians need to know when managing patients with myelofibrosis (MF). Dr Masarova highlights that physicians should avoid rapidly switching between JAK inhibitors in the first-line setting. She also emphasizes that enrollment in clinical trials and stem cell transplantation (SCT) should be at the forefront when dealing with young patients or those with an atypical disease presentation. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
